Mozambique
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2013 26 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 18 (9.4–26) 69 (36–101)
Mortality (HIV+TB only) 38 (27–51) 148 (105–198)
Prevalence  (includes HIV+TB) 140 (78–230) 559 (303–893)
Incidence  (includes HIV+TB) 140 (110–180) 552 (442–680)
Incidence (HIV+TB only) 81 (64–100) 312 (248–388)
Case detection, all forms (%) 37 (30–47)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.5 (2.2–4.8) 11 (0–25)
MDR-TB cases among notified pulmonary
TB cases
1 500 (950–2 100) 830 (0–1 900)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 23 115   2 081
Pulmonary, clinically diagnosed 20 131   2 422
Extrapulmonary 5 523    
       
Total new and relapse 53 272    
Previously treated, excluding relapses 2 948    
Total cases notified 56 220    
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 634 (3%) 653 (9%) 1 287
Laboratory-confirmed RR-/MDR-TB cases     444
Patients started on MDR-TB treatment     313
TB/HIV 2013 Number (%)
TB patients with known HIV status 51 172 (91)
HIV-positive TB patients 28 585 (56)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 27 624 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 20 449 (72)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 48 188  
Treatment success rate (%)
New cases registered in 2012 87
Previously treated cases registered in 2012 0
HIV-positive TB cases, all types, registered in 2012 0
RR-/MDR-TB cases started on second-line treatment in 2011 31
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 14
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 19
% Funded domestically  
% Funded internationally 22%
% Unfunded 78%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-31 Data: www.who.int/tb/data